Trial reportBreast cancer research and treatment2010
Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid.
Trial report in Breast cancer research and treatment, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 51 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
51 citing papers in PubMed, 1 synthesis or guideline pooled it, 96 citations in OpenAlex.
- Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010Pooled it
- Time to Mammographic Density Decrease After Exposure to Tamoxifen.The oncologist · 2022Trial
- Topical Endoxifen for Mammographic Density Reduction-A Randomized Controlled Trial.The oncologist · 2022Trial
- Perceptions of Racially and Ethnically Diverse Women at High Risk of Breast Cancer Regarding the Use of a Web-Based Decision Aid for Chemoprevention: Qualitative Study Nested Within a Randomized Controlled Trial.Journal of medical Internet research · 2021Trial
- The Role of Outcome Forecasts in Patients' Treatment Decisions--Evidence from a Survey Experiment on Knee Replacement Surgery.Health services research · 2016Trial
- Informed choice about breast cancer prevention: randomized controlled trial of an online decision aid intervention.Breast cancer research : BCR · 2013Trial
- Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid.Breast cancer research and treatment · 2011Trial
- Phase III, placebo-controlled trial of three doses of citalopram for the treatment of hot flashes: NCCTG trial N05C9.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2010Trial
- Evaluating the Implementation and Maintenance of a Breast Cancer Risk-Assessment and Prevention Program.Annals of surgical oncology · 2026Article
- Article
- Risk-management decision-making data from a community-based sample of racially diverse women at high risk of breast cancer: rationale, methods, and sample characteristics of the Daughter Sister Mother Project survey.Breast cancer research : BCR · 2024Article
- Initiation and tolerance of chemoprevention among women with high-risk breast lesions: the potential of low-dose tamoxifen.Breast cancer research and treatment · 2022Article
- Impact of national guidelines on use of BRCA1/2 germline testing, risk management advice given to women with pathogenic BRCA1/2 variants and uptake of advice.Hereditary cancer in clinical practice · 2021Article
- Risk Ladder, Table, or Bulleted List? Identifying Formats That Effectively Communicate Personalized Risk and Risk Reduction Information for Multiple Diseases.Medical decision making : an international journal of the Society for Medical Decision Making · 2021Article
- Introducing Decision Aids into Routine Prostate Cancer Care in The Netherlands: Implementation and Patient Evaluations from the Multi-regional JIPPA Initiative.Journal of cancer education : the official journal of the American Association for Cancer Education · 2020Article
- Translating Cancer Risk Prediction Models into Personalized Cancer Risk Assessment Tools: Stumbling Blocks and Strategies for Success.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2020Article
- Communicating tailored risk information of cancer treatment side effects: Only words or also numbers?BMC medical informatics and decision making · 2020Article
- Knowledge of Potential Harms and Benefits of Tamoxifen among Women Considering Breast Cancer Preventive Therapy.Cancer prevention research (Philadelphia, Pa.) · 2020Article
- Strong Evidences of the Ovarian Carcinoma Risk in Women after IVF Treatment: A Review Article.Iranian journal of public health · 2019Review
- Benefits and harms of selective oestrogen receptor modulators (SERMs) to reduce breast cancer risk: a cross-sectional study of methods to communicate risk in primary care.The British journal of general practice : the journal of the Royal College of General Practitioners · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
15 authors at 6 institutions in 1 country.
Funding
Abstract
Tamoxifen reduces primary breast cancer incidence, yet causes serious side effects. To date, few women with increased breast cancer risk have elected to use tamoxifen for chemoprevention. The objective of the study was to determine women's knowledge of and attitudes toward tamoxifen following exposure to a tailored decision aid (DA). A total of 632 women with a 5-year risk of breast cancer > or = 1.66% (Mean = 2.56, range = 1.7-17.3) were recruited from two healthcare organizations. Participants viewed an online DA that informed them about their 5-year risk of breast cancer and presented individually tailored content depicting the risks/benefits of tamoxifen prophylaxis. Outcome measures included behavioral intentions (to seek additional information about tamoxifen, to talk to a physician about tamoxifen, and to take tamoxifen); knowledge; and perceived risks and benefits of tamoxifen. After viewing the DA, 29% of participants said they intended to seek more information or talk to their doctor about tamoxifen, and only 6% believed they would take tamoxifen. Knowledge was considerable, with 63% of women answering at least 5 of 6 knowledge questions correctly. Participants were concerned about the risks of tamoxifen, and many believed that the benefits of tamoxifen did not outweigh the risks. This study is the largest to date to test women's preferences for taking tamoxifen and one of the largest to have tested the impact of a tailored DA. After viewing the DA, women demonstrated good understanding of tamoxifen's risks and benefits, but most were not interested in taking tamoxifen for breast cancer chemoprevention.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.